With 4.0% CAGR, Treatment-Resistant Depression Treatment Market Size Worth USD 20 Bn by 2031

Posted on 2022-11-06 by Fact.MR in Healthcare // 0 Comments

The global depression drugs market reached a valuation of around US$ 13 Bn in 2020, which amounts to close to 50% share of the psychotropic drugs market.

Sales of depression drugs are slated to accelerate at a CAGR of 4% to top US$ 20 Bn by 2031. Demand for serotonin-norepinephrine reuptake inhibitors (SNRIs), which hold the highest market share, is set to increase at a CAGR of 2% across the assessment period of 2021 to 2031.

To Remain ‘Ahead’ of Your Competitors, Download Report Sample :

https://www.factmr.com/connectus/sample?flag=S&rep_id=3215

Key Takeaways from Market Study

Global depression drugs market to top US$ 20 Bn by 2031.
Serotonin-norepinephrine reuptake inhibitors (SNRIs) expected to record above 2% CAGR over the next 10 years.
Major depressive disorder segment to record around 1% CAGR over the forecast period of 2021- 2031.
Market in North America holds share of more than 40%.

“Ongoing research & development, emergence of novel non-pharmacologic and pharmacologic therapies, and growth in the number of collaborations between research institutes and pharmaceutical companies are expected to boost growth of the depression drugs market over the coming years,” says a Fact.MR analyst.

Market Competition

Market players are concentrating on increasing the efficacy of depression medications while reducing their adverse effects. New companies are projected to enter the market and various product approvals are set to broaden the reach of the global market.

In February 2021, Ginger, a provider of on-demand mental healthcare, announced a collaboration with Capsule, a digital pharmacy. The goal of this collaboration was to provide Ginger members with mental health drugs, such as antidepressants, at their homes.

Share Your Requirements & Get Customized Reports :

https://www.factmr.com/connectus/sample?flag=RC&rep_id=3215

Key Companies Profiled :

Johnson and Johnson
Sebela Pharmaceutical Inc.
Takeda Pharmaceutical Company Ltd.
GlaxoSmithKline
Novartis AG
Allergan USA Inc.
AstraZeneca
Pfizer Inc.
Eli Lilly and Company
Otsuka Pharmaceutical Co. Ltd.
Alkermes Plc
Bristol Myers Squibb Co.
H. Lundbeck

Key Segments in Depression Drugs Industry Research

Drug Type
- Generic Depression Drugs
- Branded Depression Drugs
Drug Class
- Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Atypical Antipsychotics
- Central Nervous System (CNS) Stimulants
- Tricyclic Antidepressants
- Monoamine Oxidase Inhibitors
Disease Type
- Depression Drugs for Major Depressive Disorder
- Depression Drugs for Obsessive-Compulsive Disorder
- Depression Drugs for Generalized Anxiety Disorder
- Depression Drugs for Panic Disorder
- Depression Drugs for Schizophrenia
- Depression Drugs for Bipolar 1 Disorder
Distribution Channel
- Sales of Depression Drugs via Hospital Pharmacies
- Sales of Depression Drugs via Retail Pharmacies
- Sales of Depression Drugs via Online Pharmacies

Get Free Access to this Report :

https://www.factmr.com/checkout/3215

Questionnaire answered in the Depression Drugs Market report include:

How the market for Depression Drugs has grown?
What is the present and future outlook of the global Depression Drugs on the basis of region?
What are the challenges and opportunities for the Depression Drugs?
Why the consumption of Depression Drugs highest in region?
In which year segment is expected to overtake segment?

What makes Fact.MR report stand out from others?

MR follows a six-point mechanism known as E.V.O.L.V.E. (Evaluate. Visualize. Overcome. Leverage. Verify. Eradicate.). The report is specially created to assess the COVID-19 impact on the Depression Drugs market. This mechanism focuses on almost all the factors in a definite manner to provide the best research report for the market stakeholders.
Evaluate: A Fact.MR report evaluates every small aspect that can prove to be a growth generator for the Depression Drugs market, thus, making it different and special from other reports.
Visualize: The authors involved in the research activities visualized the post-COVID-19 era so that the key stakeholders of market get an overview and helps them take certain steps to ensure continuous growth during the forecast period.
Overcome: The report scrutinizes on points that can prove to be an Achilles heel to the Depression Drugs market and assists to create strategies to overcome the obstacles that may hinder the growth of the Depression Drugs market.
Leverage: The Depression Drugs market can leverage certain aspects that can prove beneficial for the increase in growth rate. Fact.MR covers all the points on which the key stakeholders can leverage upon.
Verify: Research is done systematically to assure validation of all the aspects covered in the report. All the points are rechecked and verified thoroughly to avoid flaws and fake information.
Eradicate: Last but not the least, this aspect helps the key stakeholder eradicate all the obstacles that come between the growth rate and the Depression Drugs market.

For More Insights of Fact.MR Trending Report:-

https://www.prnewswire.com/news-releases/bioceramics-use-as-lightweight-and-flexible-material-for-orthopedic-implant-to-gain-pace-at-7-by-2031-factmr-survey-301328673.html

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analysed . Our sales offices in United States and Dublin, Ireland. Reach out to us with your goals, and we’ll be an able research partner.

Matched content

Editor’s pick